Literature DB >> 6872593

Immune complexes, gallium lung scans, and bronchoalveolar lavage in idiopathic interstitial pneumonitis-fibrosis.

A F Gelb, R B Dreisen, J D Epstein, J D Silverthorne, Y Bickel, M Fields, W A Border, C R Taylor.   

Abstract

We obtained results of lung immune complexes (LIC), circulating immune complexes (CIC), 48-hour gallium lung scans (scans), bronchoalveolar lavage (BAL), and pulmonary function tests in 20 patients with idiopathic interstitial pneumonitis-fibrosis. Sixteen patients had predominantly interstitial (13 cases UIP) and/or intraalveolar (3 cases DIP) cellular disease (group 1). Prior to corticosteroid therapy in group 1, scans were positive in 75 percent, CIC were elevated in 86 percent, LIC were present in 64 percent, and BAL was abnormal in 90 percent. Duration of follow-up after treatment was 3.5 +/- 1.0 year. In group 1 after treatment with corticosteroids in 13 patients and corticosteroids and penicillamine (three patients) and plasmapheresis (one patient), only four patients remain stable or improved. After corticosteroid therapy, elevated CIC returned to normal values despite progressive patient deterioration. In three patients, lung immune complexes were still detected after circulating immune complexes had returned to normal after corticosteroid therapy. In group 2 were four patients with fibrotic disease; scans and CIC were uniformly negative, LIC were weakly present in only one patient, and BAL was abnormal in all. Despite corticosteroid therapy, all have died or deteriorated. These results suggest that positive gallium lung scans, BAL, circulating immune complexes, and to a lesser extent, lung immune complexes are associated with the cellular phase of interstitial pneumonia, but do not reliably identify a corticosteroid-responsive group.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872593     DOI: 10.1378/chest.84.2.148

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Time course of bleomycin-induced lung fibrosis.

Authors:  G Izbicki; M J Segel; T G Christensen; M W Conner; R Breuer
Journal:  Int J Exp Pathol       Date:  2002-06       Impact factor: 1.925

2.  Correlation between pulmonary fibrosis and the lung pressure-volume curve.

Authors:  R H Sansores; A Ramirez-Venegas; R Pérez-Padilla; M Montaño; C Ramos; C Becerril; M Gaxiola; P Paré; M Selman
Journal:  Lung       Date:  1996       Impact factor: 2.584

Review 3.  Molecular Imaging of Pulmonary Inflammation and Infection.

Authors:  Chiara Giraudo; Laura Evangelista; Anna Sara Fraia; Amalia Lupi; Emilio Quaia; Diego Cecchin; Massimiliano Casali
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

4.  Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Authors:  Stylianos Bournazos; Jacob Grinfeld; Karen M Alexander; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  BMC Pulm Med       Date:  2010-10-07       Impact factor: 3.317

5.  Fcγ receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis.

Authors:  Stylianos Bournazos; Irini Bournazou; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  Lung       Date:  2010-10-06       Impact factor: 2.584

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.